Denali Therapeutics, a biotechnology company focused on neurodegenerative diseases, employs 414 people worldwide. Recent staffing activity shows 73 incoming hires and 23 departures, indicating steady growth and controlled turnover. With nearly one-fifth of the workforce added in the most recent hiring cycle, the company continues to scale research, clinical, and operational capabilities while maintaining a balanced employee base.
Engineering is Denali Therapeutics’ largest team at 172 employees, representing roughly 42 % of total headcount and underscoring the company’s emphasis on scientific and technical innovation. Business Management (54) and Healthcare roles (43) form the next-largest groups, providing commercial and clinical expertise. Core operational support is distributed across Operations (36), Finance & Administration (24), and Sales & Support (14), while Human Resources and Information Technology each account for 12 employees. A diverse set of additional functions, including a small Banking & Wealth Management group and other specialized roles, round out the remaining 47 positions.
Headquarters-related roles are concentrated in the Bay Area, with 183 employees in San Francisco and 63 in South San Francisco. Additional California hubs include San Mateo (9), Los Angeles (3), and San Jose (6), illustrating the firm’s strong West Coast presence. Outside California, the company maintains teams in Salt Lake City (13), Boston (5), Chicago (5), and Zurich (5), enabling access to varied talent pools and research ecosystems. A further 122 employees work remotely or at other smaller sites, giving Denali Therapeutics a flexible and geographically diverse footprint.